Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials

Ophthalmology

Volumn 121, Issue 5, 2014, Pages 1102-1108

  Bakri, Sophie J ^a   Moshfeghi, Darius M ^b   Francom, Steve ^c   Rundle, Amy Chen ^c   Reshef, Daniel S ^c   Lee, Paul P ^d   Schaeffer, Carol ^c   Rubio, Roman G ^c   Lai, Phillip ^c  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; HUMAN; INTRAOCULAR PRESSURE; IRIDOTOMY; LASER SURGERY; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; TRABECULOPLASTY; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; RISK FACTORS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84899902138     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.11.029     Document Type: Article

References (20)

1. D.M. Brown, P.K. Kaiser, and M. Michels et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
2. S.J. Bakri, J.S. Pulido, and C.A. McCannel et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab Eye (Lond) 23 2009 181 185
3. J.E. Kim, A.V. Mantravadi, E.Y. Hur, and D.J. Covert Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents Am J Ophthalmol 146 2008 930 934
4. R.A. Adelman, Q. Zheng, and H.R. Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J Ocul Pharmacol Ther 26 2010 105 110
5. S.J. Bakri, C.A. McCannel, A.O. Edwards, and D.M. Moshfeghi Persistent ocular hypertension following intravitreal ranibizumab Graefes Arch Clin Exp Ophthalmol 246 2008 955 958
6. T.J. Good, A.E. Kimura, N. Mandava, and M.Y. Kahook Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents Br J Ophthalmol 95 2011 1111 1114
7. M.Y. Kahook, A.E. Kimura, and L.J. Wong et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections Ophthalmic Surg Lasers Imaging 40 2009 293 295
8. J.J. Tseng, S.K. Vance, and K.E. Della Torre et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration J Glaucoma 21 2012 241 247
9. S. Pershing, S.J. Bakri, and D.M. Moshfeghi Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents Ophthalmic Surg Lasers Imaging Retina 44 2013 460 464
10. S.J. Wehrli, K. Tawse, and M.H. Levin et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab Retina 32 2012 1295 1301
11. N. Ferrara, L. Damico, and N. Shams et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
12. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
13. D.M. Brown, M. Michels, and P.K. Kaiser et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study Ophthalmology 116 2009 57 65
14. SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 Arch Ophthalmol 127 2009 1101 1114
15. I.U. Scott, P.C. Vanveldhuisen, N.L. Oden SCORE Study Investigator Group Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) study: SCORE study report 14 Arch Ophthalmol 130 2012 1517 1524
16. H.A. Quigley Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson memorial lecture Am J Ophthalmol 148 2009 657 669
17. S.J. Bakri, and N.S. Ekdawi Intravitreal silicone oil droplets after intravitreal drug injections Retina 28 2008 996 1001
18. K. Kotliar, M. Maier, and S. Bauer et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model Acta Ophthalmol Scand 85 2007 777 781
19. L. Liu, D.A. Ammar, and L.A. Ross et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling Invest Ophthalmol Vis Sci 52 2011 1023 1034
20. M. Sniegowski, N. Mandava, and M.Y. Kahook Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis Open Ophthalmol J [serial online] 4 2010 28 29 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944993/ Accessed November 11, 2013